1	Inactivation analysis of SARS-CoV-2 by specimen transport media, nucleic acid extraction
2	reagents, detergents and fixatives
3	
4	Stephen R. Welch ^{a†} , Katherine A. Davies ^{a†} , Hubert Buczkowski ^{a†} , Nipunadi Hettiarachchi ^a ,
5	Nicole Green ^a , Ulrike Arnold ^{a,b} , Matthew Jones ^a , Matthew J. Hannah ^a , Reah Evans ^a , Christopher
6	Burton ^a , Jane E. Burton ^a , Malcolm Guiver ^c , Patricia A. Cane ^a , Neil Woodford ^d , Christine B.
7	Bruce ^a , Allen D. G. Roberts ^a , Marian J. Killip ^{a#}
8	
9	^a High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health
10	England, Colindale, London, UK
11	^b UK Public Health Rapid Support Team, Public Health England/London School of Hygiene and
12	Tropical Medicine, London, UK
13	^c Virology Department, Clinical Sciences Laboratory, National Infection Service, Public Health
14	England, Manchester Public Health Laboratory, Manchester, UK
15	^d NIS Laboratories, National Infection Service, Public Health England, Colindale, London, UK
16	
17	Running title: SARS-CoV-2 inactivation
18	
19	[#] Corresponding author. E-mail: marian.killip@phe.gov.uk
20	[†] Contributed equally to this work. Author order was determined on the basis of seniority.
21	
22	Key words: COVID-19; SARS-CoV-2; coronavirus; inactivation; safety testing; specimen
23	transport tubes; molecular extraction reagents; lysis buffers; clinical diagnostics;

24 Abstract

The COVID-19 pandemic has necessitated a rapid multi-faceted response by the 25 26 scientific community, bringing researchers, health officials and industry together to address the ongoing public health emergency. To meet this challenge, participants need an informed 27 approach for working safely with the etiological agent, the novel human coronavirus SARS-28 29 CoV-2. Work with infectious SARS-CoV-2 is currently restricted to high-containment laboratories, but material can be handled at a lower containment level after inactivation. Given 30 31 the wide array of inactivation reagents that are being used in laboratories during this pandemic, it 32 is vital that their effectiveness is thoroughly investigated. Here, we evaluated a total of 23 commercial reagents designed for clinical sample transportation, nucleic acid extraction and 33 virus inactivation for their ability to inactivate SARS-CoV-2, as well as seven other common 34 35 chemicals including detergents and fixatives. As part of this study, we have also tested five filtration matrices for their effectiveness at removing the cytotoxic elements of each reagent, 36 37 permitting accurate determination of levels of infectious virus remaining following treatment. In addition to providing critical data informing inactivation methods and risk assessments for 38 diagnostic and research laboratories working with SARS-CoV-2, these data provide a framework 39 40 for other laboratories to validate their inactivation processes and to guide similar studies for other pathogens. 41

43 **1.** Introduction

Infection with the novel human betacoronavirus SARS-CoV-2 can cause a severe or fatal 44 respiratory disease, termed COVID-19 (1-3). As the COVID-19 pandemic has developed, 45 millions of clinical samples have been collected for diagnostic evaluation. SARS-CoV-2 has 46 been classified as a Hazard Group 3 pathogen in the UK, and as such, deliberate work with the 47 48 virus must be carried out in high containment laboratories (containment level 3 (CL3) in the UK) with associated facility, equipment and staffing restrictions. Guidance from Public Health 49 50 England (PHE) and the World Health Organization (WHO) enable non-propagative testing of 51 clinical specimens to be carried out at the lower CL2, with the requirement that all noninactivated material is handled within a microbiological safety cabinet (MSC) and that the 52 process has been suitably and sufficiently risk assessed (4, 5). Guidance from the U.S. Centers 53 54 for Disease Control and Prevention requires that specimens must be inactivated (e.g. in nucleic 55 acid extraction buffer) before handling at biosafety level 2 (BSL-2) (6). To allow safe movement 56 of clinical samples from CL3/BSL-3 laboratories to CL2/BSL-2, virus inactivation procedures should be validated, and formal validation of inactivation protocols are often an operational 57 requirement for clinical and research laboratories handling SARS-CoV-2. 58 59 Efficacy of virus inactivation depends on numerous factors, including the nature and 60 concentration of pathogen, sample matrix, concentration of inactivation agent/s and contact time. 61 To date, there are limited data on efficacy of SARS-CoV-2-specific inactivation approaches in 62 the scientific literature and risk assessments have largely been based upon inactivation 63 information for genetically related coronaviruses. Previous studies have found that treatment 64 with heat, chemical inactivants, ultraviolet light, gamma irradiation and a variety of detergents 65 are effective at inactivating SARS-CoV-1 and Middle East Respiratory Syndrome coronavirus

(MERS-CoV), other high-consequence human coronaviruses (7–13). However, limited 66 validation data exist for coronavirus inactivation by commercial sample transport media and 67 68 molecular extraction lysis buffers used in steps prior to nucleic acid extraction for diagnostic testing. Furthermore, the precise composition of many commercial reagents is proprietary, 69 preventing ingredient-based inference of inactivation efficacy between reagents. Some limited 70 71 preliminary data on SARS-CoV-2 inactivation are available (14–19), but given the current level 72 of diagnostic and research activities, there is an urgent need to comprehensively investigate 73 SARS-CoV-2-specific inactivation efficacy of available methods to support safe virus handling. 74 An important consideration in inactivation assays is cytotoxicity, a typical effect of many chemical inactivants. To mitigate cytotoxic effects, the inactivation agent needs to be either 75 diluted out or removed from treated samples prior to testing for infectious virus. Each of these 76 77 methods for addressing cytotoxicity present their own challenges. Sample dilution requires the use of high titer stocks of virus (e.g. $>10^8$ PFU/mL) to be able to demonstrate a significant titer 78 79 reduction and reduces recovery of low level residual virus from treated samples, making it difficult or impossible to distinguish complete from incomplete virus inactivation. In contrast, 80 methods for purification of virus away from cytotoxic components in treated samples may also 81 82 remove virus or affect virus viability. Accurate quantification of remaining infectious virus ideally requires complete removal of cytotoxicity without compromising assay sensitivity, which 83 84 needs careful consideration of reagent and purification processes prior to performing inactivation 85 tests.

Here, we describe optimal methods for the removal of cytotoxicity from samples treated with commercial reagents, detergents and fixatives. These data were then used in evaluations of the effectiveness of these chemicals for inactivating SARS-CoV-2. This work, applicable to both

- 89 diagnostic and research laboratories, provides invaluable information for public health and basic
- 90 research responses to the COVID-19 pandemic by supporting safe approaches for collection,
- 91 transport, extraction and analysis of SARS-CoV-2 samples. Furthermore, our studies
- 92 investigating purification of a wide range of cytotoxic chemicals are highly applicable to
- 93 inactivation studies for other viruses, thereby supporting rapid generation of inactivation data for
- 94 known and novel viral pathogens.

96 2. Materials and Methods

97 2.1. Cells and virus

Vero E6 cells (Vero C1008; ATCC CRL-1586) were cultured in modified Eagle's 98 minimum essential medium (MEM) supplemented with 10% (v/v) fetal calf serum (FCS). Virus 99 100 used was SARS-CoV-2 strain hCOV-19/England/2/2020, isolated by PHE from the first patient 101 cluster in the UK on 29/01/2020. This virus was obtained at passage 1 and used for inactivation 102 studies at passage 2 or 3. All infectious work carried out using an MSCIII in a CL3 laboratory. 103 Working virus stocks were generated by infecting Vero E6 cells at a multiplicity of infection 104 (MOI) of 0.001, in the presence of 5% FCS. Cell culture supernatants were collected 72 hours post infection, clarified for 10 mins at $3000 \times g$, aliquoted and stored at -80°C until required. 105 106 Viral titers were calculated by either plaque assay or 50% tissue culture infectious dose 107 (TCID50). For plaque assays, 24-well plates were seeded the day before the assay (1.5×10^5) 108 cells/well in MEM/10% FCS). Ten-fold dilutions of virus stock were inoculated onto plates 109 (100µL per well), inoculated at room temperature for 1 hour then overlaid with 1.5% medium 110 viscosity carboxymethylcellulose (Sigma-Aldrich) and incubated at 37°C/5% CO₂ for 3 days. For TCID50s, ten-fold dilutions of virus stock $(25\mu L)$ were plated onto 96-well plates containing 111 Vero E6 cell suspension (2.5×10^4 cells/well in 100µl MEM/5% FCS) and incubated at 37°C/5% 112 113 CO_2 for 5-7 days. Plates were fixed with 4% (v/v) formaldehyde/PBS, and stained with 0.2% 114 (v/v) crystal violet/water TCID50 titers were determined by the Spearman-Kärber method (20, 115 21). 116

117 2.2. Reagents and chemicals used for SARS-CoV-2 inactivation

118	The commercial reagents evaluated in this study, along with their compositions (if
119	known) and manufacturers' instructions for use (if provided) are given in Supplementary Table
120	1. Specimen transport reagents tested were: Sigma Molecular Transport Medium (MM, Medical
121	Wire); eNAT (Copan); Primestore Molecular Transport Medium (MTM, Longhorn Vaccines and
122	Diagnostics); Cobas PCR Media (Roche); Aptima Specimen Transport Medium (Hologic);
123	DNA/RNA Shield, (Zymo Research); guanidine hydrochloride (GCHl) and guanidine
124	thiocyanate (GITC) buffers containing Triton X-100 (both Oxoid/Thermo Fisher); Virus
125	Transport and Preservation Medium Inactivated (BioComma). Molecular extraction reagents
126	tested were: AVL, RLT, ATL, and AL (all Qiagen); MagNA Pure external lysis buffer, and
127	Cobas Omni LYS used for on-board lysis by Cobas extraction platforms (Roche); Viral PCR
128	Sample Solution (VPSS) and Lysis Buffer (both E&O Laboratories); NeuMoDx Lysis Buffer
129	(NeuMoDx Molecular); Samba II SCoV lysis buffer (Diagnostics for the Real World);
130	NucliSENS lysis buffer (Biomerieux); Panther Fusion Specimen Lysis Tubes (Hologic); and an
131	in-house extraction buffer containing guanidine thiocyanate and Triton X-100 (PHE Media
132	Services). Detergents tested were: Tween 20, Triton X-100 and NP-40 Surfact-Amps Detergent
133	Solutions (all Thermo Scientific), and UltraPure SDS 10% solution (Invitrogen). Other reagents
134	assessed include: polyhexamethylene biguanide (PHMB, Blueberry Therapeutics);
135	Formaldehyde and Glutaraldehyde (TAAB); and Ethanol and Methanol (Fisher Scientific).
136	
127	2.3 Removal of reagent cytotoxicity

137

2.3. Removal of reagent cytotoxicity

Specimen transport tube reagents were assessed undiluted unless otherwise indicated. For
testing of molecular extraction reagents, mock samples were generated by diluting reagent in
PBS at ratios given in manufacturer's instructions. Detergents, fixatives and solvents were all

assessed at the indicated concentrations. All methods were evaluated in a spin column format, for 141 ease of sample processing within the high containment laboratory. Pierce Detergent Removal 142 143 Spin Columns (0.5mL, Thermo Scientific), Microspin Sephacryl S400HR (GE Healthcare), and Amicon Ultra-0.5mL 50KDa centrifugal filters (Merck Millipore) were prepared according to 144 manufacturer's instructions. Sephadex LH-20 (GE Healthcare) and Bio-Beads SM2 resin (Bio-145 146 Rad) were suspended in PBS and poured into empty 0.8mL Pierce centrifuge columns (Thermo Scientific), and centrifuged for one min at $1000 \times g$ to remove PBS immediately before use. For 147 148 all matrices aside from the Amicon Ultra columns, 100µl of treated sample was added to each 149 spin column, incubated for two mins at room temperature, then eluted by centrifugation at 1,000 \times g for two mins. For Amicon Ultra filters, 500µl of sample was added, centrifuged at 14,000 \times g 150 151 for 10 mins, followed by three washes with 500µl PBS. Sample was then collected by 152 resuspending contents of the filtration device with 500µl PBS. To assess remaining cytotoxicity, 153 a two-fold dilution series of treated filtered sample was prepared in PBS, and 6.5µl of each dilution transferred in triplicate to 384-well plates containing Vero E6 cells (6.25×10^3 cells/well 154 in 25µl MEM/5%FCS) and incubated overnight. Cell viability was determined by CellTiter 155 Aqueous One Solution Cell Proliferation Assay (Promega) according to manufacturer's 156 157 instructions. Normalized values of absorbance (relative to untreated cells) were used to fit a 4-158 parameter equation to semilog plots of the concentration-response data, and to interpolate the 159 concentration that resulted in 80% cell viability (CC20) in reagent treated cells. All analyses 160 were performed using GraphPad Prism 8 (v8.4.1, GraphPad Software). 161

162 2.4. SARS-CoV-2 inactivation

For commercial products, virus preparations (tissue culture fluid, titers ranging from $1 \times$ 163 10^6 to 1×10^8 PFU/ml) were treated in triplicate with reagents at concentrations and for contact 164 times recommended in the manufacturers' instructions for use, where available, or for 165 concentrations and times specifically requested by testing laboratories. Where a range of 166 167 concentrations was given by the manufacturer, the lowest ratio of product to sample was tested 168 (i.e. lowest recommended concentration of test product). Specimen transport tube reagents were 169 tested using a ratio of one volume of tissue culture fluid to ten volumes of reagent, unless a 170 volume ratio of sample fluid to reagent was specified by the manufacturer. Detergents, fixatives 171 and solvents were tested at the indicated concentrations for the indicated times. For testing of alternative sample types, virus was spiked into the indicated sample matrix at a ratio of 1:9, then 172 173 treated with test reagents as above. All experiments included triplicate control mock-treated 174 samples with an equivalent volume of PBS in place of test reagent. Immediately following the 175 required contact time, 1mL of treated sample was processed using the appropriately selected 176 filtration matrix. Reagent removal for inactivation testing was carried out in a larger spin column format using Pierce 4mL Detergent Removal Spin Columns (Thermo Fisher), or by filling empty 177 Pierce 10mL capacity centrifuge columns (Thermo Fisher) with SM2 Bio-Beads, Sephacryl S-178 179 400HR or Sephadex LH-20 to give 4mL packed beads/resin. For purification using Amicon 180 filters, $2 \times 500 \mu$ l samples were purified using two centrifugal filters by the method previously 181 described, then pooled together. For formaldehyde and formaldehyde with glutaraldehyde 182 removal, one filter was used with $1 \times 500 \mu l$ sample volume, resuspended after processing in 500µl PBS, and added to 400ul MEM/5% FBS. For inactivation of infected monolayers, 12.5 183 cm^2 flasks of Vero E6 cells (2.5 × 10⁶ cells/flask in 2.5mL MEM/5% FBS) were infected at MOI 184 185 0.001 and incubated at $37^{\circ}C/5\%$ CO₂ for 24 hours. Supernatant was removed, and cells fixed

186	using 5mL of formaldehyde, or formaldehyde and glutaraldehyde at room temperature for 15 or
187	60 mins. The fixative was removed, and monolayers washed three times with PBS before
188	scraping cells into 1mL MEM/5% FBS and sonicated (3×10 second on,10 seconds off at 100%
189	power and amplitude) using a UP200St with VialTweeter attachment (Hielscher Ultrasound
190	Technology). Supernatants were clarified by centrifuging at $3000 \times g$ for 10 mins.
191	
192	2.5. SARS-CoV-2 quantification and titer reduction evaluation
193	Virus present in treated and purified, or mock-treated and purified, samples was
194	quantified by either TCID50 or plaque assay. As additional assay controls, unfiltered mock-
195	treated sample was titrated to determine virus loss during filtration, and filtered test-reagent only
196	(no virus) sample titrated to determine residual test buffer cytotoxicity. For TCID50 assays, neat
197	to 10^{-7} ten-fold dilutions were prepared, and for plaque assays, neat to 10^{-5} ten-fold dilutions
198	were prepared, both in MEM/5% FCS. TCID50 titers were determined by the Spearman-Kärber
199	method (20, 21). Conditions where low levels of virus were detected such that TCID50 could not
200	be calculated by Spearman-Kärber, TCID50 was calculated the Taylor method (22). Where no
201	virus was detectable, values are given as less than or equal to the Taylor-derived TCID50 titer
202	given by a single virus positive well at the lowest dilution where no cytotoxicity was observed.
203	Titer reduction was calculated by subtracting the mean logarithmic virus titer for test-buffer-
204	treated, purified conditions from the mean logarithmic virus titer for the PBS-treated, purified
205	condition, with standard errors calculated according to (22).
206	

207 2.6. Serial passages of treated samples

208	In parallel to virus quantification, 12.5 cm ² flasks of Vero E6 cells (6.25×10^4 cells/flask
209	in 2.5mL MEM/5% FBS) were inoculated with either 500µl or 50µl of treated filtered sample.
210	Flasks were examined for cytopathic effect (CPE) and 500µl culture medium from each flask
211	was used to inoculate new 12.5 cm ² flasks of Vero E6 cells after seven days. If no CPE was
212	observed, this process was continued for up to four serial passages. For the duration of the
213	passage series, a flask of untreated cells was included as a control for cross-contamination
214	between flasks, and a SARS-CoV-2 infected control was included to ensure suitable conditions
215	for virus propagation. To distinguish CPE from any residual cytotoxicity associated with test
216	reagents, samples of cell culture medium were taken from each flask at the beginning and end of
217	each passage. Nucleic acid was extracted from cell culture media manually using a QIAamp
218	Viral RNA Mini Kit (QIAGEN) or using NucliSENS easyMAG or EMAG platforms (both
219	BioMérieux). Viral RNA levels were quantified by quantitative reverse-transcriptase PCR (qRT-
220	PCR) specific for the SARS-CoV-2 E gene (23) using TaqMan Fast 1-Step Master Mix (Applied
221	Biosystems) on a 7500 Fast Real-Time PCR System (Applied Biosystems). A positive result for
222	virus amplification was recorded if effects on the monolayer consistent with CPE and a decrease
223	in Ct across the course of a passage were observed.

225 **3. Results**

3.1. Reagent filtration optimization to minimize cytotoxicity and maximum virus recovery

Prior to evaluating their effectiveness at inactivating SARS-CoV-2, we investigated the 228 229 cytotoxicity of each reagent before and after filtration though one of five matrices: Sephadex 230 LH-20, Sephacryl S400HR, Amicon Ultra 50kDa molecular weight cut-off centrifugal filters, Pierce detergent removal spin columns (DRSC), and Bio-Beads SM2 nonpolar polystyrene 231 232 adsorbents. Reagents were diluted with PBS to the working concentrations recommended by the 233 manufacturer (for commercial sample transport and molecular extraction reagents), or the indicated concentrations (for all other chemicals), followed by a single reagent removal step with 234 235 each filtration matrix. Dilution series of filtered and unfiltered samples were generated to 236 determine concentration-dependent cytotoxicity, from which the CC20 value for each 237 combination of reagent and filtration method were interpolated (Supplementary Figure 1). CC20 238 was chosen as, at this concentration, cells retain 80% viability and enable distinction of active SARS-CoV-2 replication by visualisation of CPE in the monolayer. Table 1 shows the dilution 239 factor of reagent-treated sample required to achieve the CC20 after filtration, with <1 indicating 240 241 complete removal of cytotoxicity. These data were used to determine the relative cytotoxicity removed by one filtration step for each combination of reagent and matrix (Figure 1A). 242

All unfiltered reagents tested here were cytotoxic, but the degree of cytotoxicity varied considerably as did the optimal filtration matrix for each reagent. The detergent Tween 20 used at 1% concentration was the least cytotoxic unfiltered, only requiring a dilution factor of 7.7 to reach the CC20, although only the Bio-Bead SM2 filters were effective at removing all cytotoxicity. The chemical fixative combination of 2% formaldehyde plus 1.5% glutaraldehyde

248	was the most cytotoxic unfiltered, requiring a dilution of over 4000 to reach the CC20, with only
249	the Amicon Ultra columns able to remove 100% of the cytotoxicity. However, for the majority
250	reagents (27/34) tested, filtration through at least one matrix type removed 100% of cytotoxicity
251	allowing neat eluate to be used directly in cell culture without further dilution. There were
252	several exceptions to this: DNA/RNA shield (maximum 99.4% cytotoxicity removal using
253	SM2); 40% GHCl (99.1% using Pierce DRSC); 4M GITC (99.7% using Pierce DRSC); MagNA
254	Pure (99.7% using SM2); AL buffer (87.4% using S400HR); Cobas Omni LYS (97.0% using
255	SM2); and NeuMoDx (93.4% using S400HR). For these reagents, filtered eluate was still
256	cytotoxic when used undiluted in cell culture. However, CC20 values indicated that this
257	remaining cytotoxicity would be removed by first or second $(10^{-1} - 10^{-2})$ dilutions in the TCID50
258	assay allowing evaluation of titer reduction using these reagents with the caveat that the effective
259	assay limit of detection (LOD) would be higher. Passing treated samples through more than one
260	column, or increasing the depth of the resin/bead bed within the spin column can also improve
261	cytotoxicity removal for some reagents (unpublished data).
262	In addition to cytotoxicity removal, a successful filtration method must also purify virus
263	without adversely affecting titer or integrity. We therefore assessed SARS-CoV-2 recovery after
264	each filtration method. Using an input titer of 1.35×10^6 TCID50/mL, triplicate purifications of
265	virus through Sephadex LH-20 or Pierce detergent removal spin columns resulted in recovery of
266	100% of input virus (Figure 1B). In contrast, the recoverable titer after one filtration through
267	Amicon Ultra filters was 2.13×10^5 TCID50/mL, an 85% reduction from input. Purification with

268 S400HR and Bio-Beads SM2 matrices resulted in recoverable titers of 1.08×10^6 TCID50/mL

and 8.99×10^5 TCID50/mL, a loss of 30% and 35% of input virus, respectively.

271 **3.2.** SARS-CoV-2 inactivation by specimen transport and molecular extraction reagents

Specimen transport tubes are designed to inactivate microorganisms present in clinical 272 specimens prior to sample transport, while preserving the integrity of nucleic acids for molecular 273 274 testing. If effective, these products have the potential to streamline SARS-CoV-2 diagnostic 275 processing in testing laboratories by eliminating the requirement for CL3 processing or, for 276 activities derogated to CL2, permitting processing outside an MSC. The BS EN 14476 standard requires demonstration of a >4 \log_{10} titer reduction for virucidal suspension tests (22), and we 277 278 were able to demonstrate a $\geq 4 \log 10$ TCID50 titer reduction for all specimen transport media 279 evaluated in a tissue culture fluid matrix (Table 2). However, infectious virus remained recoverable in treated samples after inactivation with most reagents tested (by either TCID50 or 280 281 blind passage). The exceptions to this were PrimeStore MTM and 4M GITC, from which no 282 residual virus was detectable by either TCID50 or by the passaging of treated purified sample. 283 While several contact times were evaluated for all these reagents, length of contact time had no 284 effect on either the level of virus titer reduction or whether virus remained detectable upon 285 passage.

We also sought to inform sample processing by examining inactivation by molecular 286 287 extraction lysis buffers used in several manual and automated extraction protocols within SARS-CoV-2 diagnostic and research laboratories. We could demonstrate a \geq 4 log10 reduction in 288 289 TCID50 titer for all but two molecular extraction reagents when evaluated using tissue culture 290 fluid (Table 3). The exceptions to this were AL and Cobas Omni LYS, where remaining cytotoxicity in the filtered eluate increased the TCID50 LOD to a level such that the maximum 291 292 calculable titer reductions were \geq 3.5 and \geq 3.9 log10 TCID50s, respectively. However, given no 293 virus was detected at any passage it is likely that infectious virus was effectively inactivated by

294 these two reagents. For reagents tested with multiple contact times (NucliSENS, Panther Fusion), shorter times (10 mins) were as effective at reducing virus titers as longer contact times. Most 295 296 reagents reduced viral titers to around the TCID50 assay LOD, indicating that any remaining virus post treatment was present only at very low titers (<10 TCID50/mL), but higher levels of 297 virus were recoverable from samples treated with some extraction buffers. For NeuMoDx lysis 298 299 buffer, although titers were reduced by $\geq 4 \log 10 \text{ TCID50s}$, an average of 91 (±38) TCID50/mL 300 remained detectable. Similarly, Buffer AVL reduced virus titers by 5.1 log10 TCID50s, but after 301 treatment virus was detectable in all treated samples replicates (average 54 (\pm 18) TCID50/mL). 302 However, addition of four sample volumes of absolute ethanol following a 10 minute contact time with AVL (the next step in the QIAGEN Viral RNA Mini Kit manual), a \geq 5.9 log10 titer 303 reduction was recorded with no virus recoverable following passages in cell culture. 304 305 Panther Fusion lysis buffer was further tested against a relevant clinical sample matrix, 306 pooled fluid from oropharyngeal (OP) and nasopharyngeal (NP) swab specimens, resulting in a 307 \geq 5.1 log10 titer with no remaining infectious virus detectable. We additionally evaluated the tissue lysis buffer RLT using homogenised ferret lung as sample material, with treatment 308 resulting in a \geq 4.8 log10 titer reduction with no residual infectious virus detectable. 309

310

311 **3.3.** SARS-CoV-2 inactivation by detergents

312 Detergents can be used to inactivate lipid enveloped viruses such as coronaviruses by 313 disrupting the viral envelope, therefore rendering them unable to attach or enter cells (24–27).

Here, we evaluated Triton X-100, SDS, NP40 and Tween 20 for their ability to inactivate SARS-

315 CoV-2. SDS treatment at 0.1% or 0.5% reduced titers by \geq 5.7 and \geq 6.5 log10 TCID50s,

respectively, while both concentrations of NP40 reduced titers by $\geq 6.5 \log 10 \text{ TCID50}$ with no

317	residual v	virus detectable following NP40 treatment. In contrast, up to 0.5% Tween 20 had no
318	effect on	viral titers. Triton X-100 is commonly used in viral inactivation reagents, and here we
319	show that	t at both 0.1% and 0.5% v/v concentration, virus titers in tissue culture fluid were
320	reduced b	by \geq 4.9 log10 TCID50s, even with less than 2 min contact time (Table 4). Furthermore,
321	we were	unable to recover infectious virus from samples treated with 0.5% Triton X-100 for 10
322	mins or le	onger. We also saw effective inactivation of SARS-CoV-2 by SDS, NP40 and Triton X-
323	100 in sp	iked NP and OP swab specimen fluid, but, importantly, we were not able to replicate
324	this in spi	iked serum; 1% Triton X-100 only reduced titers in human serum by a maximum of 2
325	log10 TC	CID50s with contact times of up to two hours.
326	In	addition to evaluating inactivation efficacy by detergents, we assessed the effects of
327	treatment	t on RNA integrity to determine their suitability for inactivation prior to nucleic acid
328	testing. E	Extracted RNA from treated samples was tested using a SARS-CoV-2-specific qRT-
329	PCR, and	the Ct difference between detergent-treated samples and mock-treated controls
330	determine	ed (Table 4). A time-dependent increase in Ct value following treatment with 0.5%
331	Triton X-	-100 was observed, indicating a detrimental effect on RNA stability with increasing
332	treatment	t times. Treatment with NP40 had a marked effect, with a 30 minute treatment leading
333	to an incr	rease in 9-10 Cts. While we saw no increase in Ct in tissue culture fluid samples treated
334	with 0.5%	6 SDS, we observed an increase in Ct for SDS-treated swab fluid samples, likely due to
335	an increas	sed concentration of RNases in clinical samples.
336		
337	3.4. SA	ARS-CoV-2 inactivation by other chemical treatments

Fixation and inactivation of viruses by addition of formaldehyde, or a combination offormaldehyde and glutaraldehyde, is a well-established protocol, particularly for diagnostic

340 electron microscopy (28, 29). 4% or 2% formaldehyde treatment for 15 or 60 mins reduced virus titers by \geq 4.8 log10 TCID50s when evaluated against a tissue culture fluid matrix, with no 341 remaining infectious virus detectable (Table 5). When infected monolayers were subjected to the 342 343 same treatment protocol, titer reductions were all $\geq 6.8 \log 10 \text{ TCID50s}$, with 60 min contact time 344 moderately more effective than 15 min. However, in this format, a 60 min 4% formaldehyde 345 treatment was the only one from which no infectious virus was detectable. A mixture of 2% formaldehyde with 1.5% glutaraldehyde tested on infected monolayers reduced virus titers by 346 \geq 6.7 log10 TCID50s with no remaining infectious virus detectable for both a 15 and 60 min 347 348 contact time. Polyhexanide biguanide (PHMB) is a polymer used as a disinfectant and antiseptic, 349 evaluated here as a potential lysis buffer, but it was only able to reduce viral titers by 1.6 log10 350 TCID50s at the highest concentration tested (2%).

352 **4. Discussion**

Samples containing infectious SARS-CoV-2 require an initial inactivation step before 353 downstream processing; given the rapid emergence of SARS-CoV-2, these inactivation protocols 354 have been guided by existing data for other coronaviruses and there is an urgent need to both 355 confirm these historical data using the new virus and to validate new approaches for inactivating 356 357 SARS-CoV-2. We therefore analysed numerous commercially and commonly available reagents 358 used by public health agencies and research laboratories around the world in their response to the 359 pandemic. In addition, to address challenges of reagent cytotoxicity in inactivation evaluation, 360 we provide data on the effectiveness of filtration methods for removing cytotoxicity from chemically treated samples. 361

Knowledge of the expected amount of infectious virus in clinical samples obtained from 362 363 COVID-19 patients is important when applying viral inactivation study data to diagnostic sample 364 processing, allowing end users to interpret whether material they are handling is likely to 365 represent an infectious risk to themselves and others. These values are dependent on several 366 factors, including time post symptom onset, duration of symptoms, time elapsed between sampling and testing, the presence of neutralizing antibody responses, and immunocompetency 367 368 of the individual (30). Data regarding quantitative infectious viral levels in typical clinical 369 specimens are minimal, with most studies reporting viral loads determined by qRT-PCR only 370 (31-33). One study of 90 qRT-PCR positive NP or endotracheal (ETT) samples from COVID-19 371 patients estimated the median titer at 3.3 log10 TCID50/mL (30). Given we demonstrate >4 log₁₀ 372 reduction in titer for all specimen transport reagents, this suggests that these reagents may 373 considerably decrease, even eliminate, the infectivity of a clinical sample. However, our 374 observation that residual virus could be recovered from most treated samples indicates that these

media cannot be assumed to completely inactivate SARS-CoV-2 in samples and that additional
precautionary measures should be taken in laboratories when it comes to sample handling and
transport.

Limited SARS-CoV-2 inactivation data on molecular extraction reagents used in nucleic 378 379 acid detection assays are currently available. One study reported that Buffer AVL either alone or 380 in combination with ethanol was not effective at completely inactivating SARS-CoV-2 (15). By 381 contrast, we could not recover any infectious virus from samples treated with AVL plus ethanol, 382 consistent with previous studies indicating that AVL and ethanol in combination is effective at 383 inactivating MERS and other enveloped viruses (10, 34), and indicating that both AVL and ethanol steps of manual extraction procedures should be performed before removal of samples 384 from primary containment for additional assurance. Our detergent inactivation data, indicating 385 386 that SDS, Triton X-100 and NP40, but not Tween 20, can effectively inactivate SARS-CoV-2 in 387 tissue culture fluid and in pooled NP and OP swab fluid, corroborate findings of a recent study 388 (17); however, as has been demonstrated for other viruses (31), we observed an inhibitory effect of serum on virus inactivation by detergent, highlighting the importance of validating 389 inactivation methods with different sample types. 390

Based on our findings comparing filtration matrices, we found that the optimum method for reagent removal for inactivation studies is determined by evaluating three factors: (i) effectiveness of cytotoxicity removal; (ii) efficiency of virus recovery; and (iii) the ease of performing these methods within a containment space. Methods permitting complete removal of cytotoxic reagent components with no or little effect on virus recovery give assurance that low levels of residual virus, if present, could be detected in virus inactivation studies. During reagent testing, there were several instances where we noted residual cytotoxicity in the neat eluate

contrary to what was expected based on the initial reagent removal data and is likely due to the
extended incubation period required for inactivation testing (up to 7 days, compared with
overnight for cytotoxicity evaluation). In all cases however, we were still able to enhance the
levels of titer reduction detectable when compared with what would have been achieved by
sample dilution alone.

403 In conclusion, we have evaluated methods for straightforward, rapid determination of purification options for any reagent prior to inactivation testing, enabling establishment of 404 405 effective methods for sample purification while minimising virus loss. This is applicable to 406 inactivation studies for all viruses (known and novel), not only SARS-CoV-2. We have applied these methods to obtain SARS-CoV-2 inactivation data for a wide range of reagents in use (or 407 proposed for use) in SARS-CoV-2 diagnostic and research laboratories. In addition to guiding 408 409 laboratory risk assessments, this information enables laboratories to assess alternative reagents 410 that may be used for virus inactivation and nucleic acid extraction, particularly considering 411 concerns about extraction reagent availability due to increased global demand caused by the COVID-19 pandemic. Furthermore, chemical treatments evaluated here are commonly used for 412 inactivation of a wide range of different viruses and other pathogens, and the results presented 413 414 may be used to directly inform and improve the design of future inactivation studies.

415 Acknowledgments

- 416 The authors would like to thank: The Respiratory Virus Unit at PHE Colindale, and the Virology
- 417 Laboratories at PHE Cambridge and PHE Bristol for donation of pooled respiratory samples; and
- 418 Ayoub Saei at the Statistics Unit, PHE Colindale for statistical advice.

- 420 The views expressed in this article are those of the author(s) and are not necessarily those of
- 421 Public Health England or the Department of Health and Social Care
- 422
- 423

424 **References**

- 1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses.
- 426 2020. The species Severe acute respiratory syndrome-related coronavirus: classifying
- 427 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5:536–544.
- 428 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu
- 429 T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang
- 430 G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients infected with
- 431 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506.
- 432 3. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-
- 433 Y, Yuan M-L, Zhang Y-L, Dai F-H, Liu Y, Wang Q-M, Zheng J-J, Xu L, Holmes EC,
- Zhang Y-Z. 2020. A new coronavirus associated with human respiratory disease in China.
 Nature 579:265–269.
- 436 4. Public Health England. 2020. COVID-19: guidance for sampling and for diagnostic437 laboratoriesitle.
- 438 5. World Health Organization. Laboratory biosafety guidance related to the novel
 439 coronavirus (2019-nCoV).
- 6. Centers for Disease Control and Prevention. Interim Guidelines for Biosafety andCOVID-19.
- 442 7. Rabenau HF, Biesert L, Schmidt T, Bauer G, Cinatl J, Doerr HW. 2005. SARS-
- 443 coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated
- immunoglobulin preparation. Biologicals 33:95–9.
- 8. Rabenau HF, Kampf G, Cinatl J, Doerr HW. 2005. Efficacy of various disinfectants
- against SARS coronavirus. J Hosp Infect 61:107–111.

447	9.	Leclercq I, Batéjat C, Burguière AM, Manuguerra J-C. 2014. Heat inactivation of the
448		Middle East respiratory syndrome coronavirus. Influenza Other Respi Viruses 8:585–6.
449	10.	Kumar M, Mazur S, Ork BL, Postnikova E, Hensley LE, Jahrling PB, Johnson R,
450		Holbrook MR. 2015. Inactivation and safety testing of Middle East Respiratory Syndrome
451		Coronavirus. J Virol Methods 223:13–18.
452	11.	Darnell MER, Subbarao K, Feinstone SM, Taylor DR. 2004. Inactivation of the
453		coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J Virol Methods
454		121:85–91.
455	12.	Darnell MER, Taylor DR. 2006. Evaluation of inactivation methods for severe acute
456		respiratory syndrome coronavirus in noncellular blood products. Transfusion 46:1770-
457		1777.
458	13.	Kariwa H, Fujii N, Takashima I. 2004. Inactivation of SARS coronavirus by means of
459		povidone-iodine, physical conditions, and chemical reagents. Jpn J Vet Res 52:105–112.
460	14.	Mantlo E, Evans A, Patterson-Fortin L, Boutros J, Smith R, Paessler S. 2020. Efficacy of
461		a novel iodine complex solution, CupriDyne, in inactivating SARS-CoV-2. bioRxiv Prepr
462		Serv Biol.
463	15.	Pastorino B, Touret F, Gilles M, Luciani L, de Lamballerie X, Charrel RN. 2020.
464		Evaluation of Chemical Protocols for Inactivating SARS-CoV-2 Infectious Samples.
465		Viruses 12.
466	16.	Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. 2020. Rapid In-
467		Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
468		Using Povidone-Iodine Oral Antiseptic Rinse. J Prosthodont Off J Am Coll Prosthodont.
469	17.	Patterson EI, Prince T, Anderson ER, Casas-Sanchez A, Smith SL, Cansado-Utrilla C,

- 470 Turtle L, Hughes GL. 2020. Methods of inactivation of SARS-CoV-2 for downstream
 471 biological assays. bioRxiv Prepr Serv Biol.
- 18. Bain W, Lee JS, Watson AM, Stitt-Fischer MS. 2020. Practical Guidelines for Collection,
- 473 Manipulation and Inactivation of SARS-CoV-2 and COVID-19 Clinical Specimens. Curr
- 474 Protoc Cytom 93:e77.
- 475 19. Jureka AS, Silvas JA, Basler CF. 2020. Propagation, Inactivation, and Safety Testing of
 476 SARS-CoV-2. Viruses 12.
- 477 20. Spearman Cjbj. 1908. The method of right and wrong cases (constant stimuli) without
 478 Gauss's formulae. Br J Psychol 2:227.
- 479 21. Kärber G. 1931. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche.
 480 Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 162:480–483.
- 481 22. British Standards Institution. 2019. Chemical disinfectants and antiseptics. Quantitative
- 482 suspension test for the evaluation of virucidal activity in the medical area. Test method483 and requirements (Phase 2/Step 1).
- 484 23. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink
- 485 S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink
- 486 S, Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H,
- 487 Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019488 nCoV) by real-time RT-PCR. Euro Surveill 25.
- 489 24. Tempestilli M, Pucci L, Notari S, Di Caro A, Castilletti C, Rivelli MR, Agrati C, Pucillo
- 490 LP. 2015. Diagnostic performances of clinical laboratory tests using Triton X-100 to
- 491 reduce the biohazard associated with routine testing of Ebola virus-infected patients. Clin
- 492 Chem Lab Med 53:1967–73.

- 493 25. Krebs FC, Miller SR, Malamud D, Howett MK, Wigdahl B. 1999. Inactivation of human
- 494 immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium
- dodecyl sulfate. Antiviral Res 43:157–73.
- 496 26. Remy MM, Alfter M, Chiem M-N, Barbani MT, Engler OB, Suter-Riniker F. 2019.
- 497 Effective chemical virus inactivation of patient serum compatible with accurate
- 498 serodiagnosis of infections. Clin Microbiol Infect 25:907.e7-907.e12.
- 499 27. Kawahara T, Akiba I, Sakou M, Sakaguchi T, Taniguchi H. 2018. Inactivation of human
- and avian influenza viruses by potassium oleate of natural soap component through
- 501 exothermic interaction. PLoS One 13:e0204908.
- 502 28. Hazelton PR, Gelderblom HR. 2003. Electron microscopy for rapid diagnosis of infectious
 503 agents in emergent situations. Emerg Infect Dis 9:294–303.
- 504 29. Möller L, Schünadel L, Nitsche A, Schwebke I, Hanisch M, Laue M. 2015. Evaluation of
- virus inactivation by formaldehyde to enhance biosafety of diagnostic electron
 microscopy. Viruses 7:666–79.
- 30. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, Boodman C, Bello A,
- Hedley A, Schiffman Z, Doan K, Bastien N, Li Y, Van Caeseele PG, Poliquin G. 2020.
- 509 Predicting infectious SARS-CoV-2 from diagnostic samples. Clin Infect Dis.
- 510 31. van Kampen JJA, Tintu A, Russcher H, Fraaij PLA, Reusken CBEM, Rijken M, van
- 511 Hellemond JJ, van Genderen PJJ, Koelewijn R, de Jong MD, Haddock E, Fischer RJ,
- 512 Munster VJ, Koopmans MPG. 2017. Ebola Virus Inactivation by Detergents Is Annulled
- 513 in Serum. J Infect Dis 216:859–866.
- 514 32. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, Yip CC-Y, Cai J-P,
- 515 Chan JM-C, Chik TS-H, Lau DP-L, Choi CY-C, Chen L-L, Chan W-M, Chan K-H, Ip JD,

516	Ng AC-K. Pool	n RW-S. Luo C-7	Cheng VC-C	Chan JF-W.	Hung IF-N.	Chen Z, Chen H

- 517 Yuen K-Y. 2020. Temporal profiles of viral load in posterior oropharyngeal saliva
- samples and serum antibody responses during infection by SARS-CoV-2: an observational
- cohort study. Lancet Infect Dis 20:565–574.
- 520 33. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D,
- 521 Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann
- 522 R, Zwirglmaier K, Drosten C, Wendtner C. 2020. Virological assessment of hospitalized
- 523 patients with COVID-2019. Nature 581:465–469.
- 524 34. Smither SJ, Weller SA, Phelps A, Eastaugh L, Ngugi S, O'Brien LM, Steward J, Lonsdale
- 525 SG, Lever MS. 2015. Buffer AVL Alone Does Not Inactivate Ebola Virus in a
- 526 Representative Clinical Sample Type. J Clin Microbiol 53:3148–3154.

Table 1: Purification of reagents: Values [95% CI] represent the dilution factor required after one purification process to achieve the CC20 concentration [95% CI].

Туре	Reagent	Reagent:media	Post-filtration dilution factor of eluate needed for CC20							
		ratio or %v/v	Unpurified	Sephadex LH-20	Sephacryl S400HR	Amicon Ultra 50kDa	Pierce DRSC	Bio-Beads SM2		
	BioComma	10:1	36.2 [30.1 - 44.0]	<2 [n/a]	<2 [n/a]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	12.1 [9.2 – 16.4]		
	Sigma MM	1.5:1	417 [<i>306 – 619</i>]	59.2 [51.8 – 67.1]	48.7 [44.6 – 53.3]	4.0 [3.6 – 4.3]	<1 [<i>n/a</i>]	7.6 [6.5 – 8.9]		
	eNAT	3:1	70.1 [55.0 – 88.5]	<1 [<i>n/a</i>]	2.8 [2.5 – 3.1]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	24.4 [20.2 - 30.2]		
Specimen	Primestore MTM	3:1	56.2 [47.2 - 66.3]	<1 [<i>n/a</i>]	4.8 [<i>nc</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	18.3 [15.4 – 22.1]		
Transport	Cobas PCR Media	1:1	55.5 [46.5 - 67.5]	2.7 [2.3 – 3.1]	5.2 [<i>4.6 – 5.9</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	26.5 [23.5 – 30.2]		
Tube Reagent	DNA/RNA Shield	10:1	1098 [<i>994 – 1231</i>]	1155 [<i>1076 – 1253</i>]	82.3 [<i><82.3 – 94.7</i>]	29.6 [26.2 – 32.3]	66.1 [<i>58.1</i> – 75.8]	7.1 [5.5 – 8.6]		
neagent	40% GHCI/Tx TM	10:1	245 [<i>205 – 288</i>]	24.5 [<24.5 - 31.5]	25.9 [<25.9 – 36.7]	13.3 [<i><13.3 – 15.6</i>]	2.2 [nc]	119 [<i>103 – 135</i>]		
	2M GITC/Tx TM	10:1	245 [<i>215 – 277</i>]	19.4 [<19.4 – 23.9]	19.1 [15.4 – 26.3]	37.8 [nc]	<1 [<i>n/a</i>]	127 [113 – 141]		
	4M GITC/Tx TM	10:1	1054 [889 - 1262]	545 [487 - 613]	141 [<i>102 – 201</i>]	211 [<i>172 – 247</i>]	3.5 [<i>3.1 - 3.9</i>]	20.3 [15.2 - 27.9]		
	Buffer AVL	4:1	61.6 [50.8 – 75.1]	<1 [n/a]	3.2 [<i>2.9 – 3.5</i>]	<1 [n/a]	<1 [n/a]	26.1 [21.5 – 32.3]		
	MagNA Pure LB	1:1	1934 [<i>1348 – 2780</i>]	1391 [<1391–1654]	474 [434 – 517]	346 [<346 – 382]	59.1 [45.6 – 70.4]	5.8 [<i>1.4 – 7.8</i>]		
	NucliSENS	1:1	60.5 [<i>54.9 – 66.2</i>]	<1 [<i>n/a</i>]	4.3 [4.0 – 4.9]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	4.6 [<4.6 - 6.7]		
	Panther Fusion	1.42:1	196 [<196 – 214]	<1 [<i>n/a</i>]	18.0 [<18.0 - 19.4]	15.9 [<15.9 – 16.5]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]		
	Buffer AL	1:1	61.9 [56.7 – 65.4]	37.4 [34.7 – 41.1]	7.8 [6.6 – 9.3]	30.5 [25.5 – 36.3]	29.5 [25.9 – 33.9]	16.5 [<i>14.6 – 18.9</i>]		
Molecular	Cobas Omni LYS	1:1	225 [<225 – 255]	142 [nc]	45.8 [<45.8 – 55.6]	117 [<i>nc</i>]	16.7 [nc]	6.7 [2.9 – 8.7]		
Extraction Reagents	PHE in-house LB	4:1	231 [<231 – 310]	26.2 [22.0 - 31.8]	11.4 [9.9 - 13.2]	2.7 [<2.7 - 4.9]	<1 [<i>n/a</i>]	12.9 [<i>9.8 - 17.9</i>]		
Reagents	NeuMoDx LB	1:1	30.2 [24.1 - 37.9]	8.0 [7.3 - 8.8]	2.0 [1.7 – 2.4]	7.5 [6.6 - 8.1]	4.2 [0.4 - 6.9]	6.8 [<6.8 - 8.4]		
	E&O Labs VPSS	10:1	174 [145 – 206]	24.9 [22.1 - 28.4]	14.2 [11.7 - 17.5]	7.7 [<7.7 - 14.5]	<1 [n/a]	11.7 [8.5 – 16.4]		
	E&O Lab LB	10:1	69.0 [<i>62.7 – 76.9</i>]	9.5 [<9.5 – 11.0]	8.0 [7.4 – 8.7]	2.2 [nc]	<1 [<i>n/a</i>]	4.1 [3.5 – 4.7]		
	Samba SCoV LB	10:1	177 [<177 – 213]	68.2 [63.0 - 75.4]	27.3[24.2 - 30.1]	5.2 [<5.2 - 6.0]	<1 [n/a]	1.5 [1.0 – 1.8]		
	Buffer RLT	9:1	48.0 [<i>40.3 – 58.0</i>]	2.9 [2.3 – 4.3]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	18.5 [15 <i>.3 – 22.8</i>]		
	Triton-X100	1%	185 [<185 – 211]	48.4 [<48.4 - 58.4]	~17.22 [nc]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]		
Determente	Tween 20	1%	7.7 [6.9 – 8.6]	4.2 [<3.8 – 4.9]	1.3 [1.0 – 1.7]	4.4 [4.0 - 5.1]	4.9 [3.4 – 7.5]	<1 [<i>n/a</i>]		
Detergents	SDS	1%	69.6 [n/a]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]		
	NP40	1%	320 [<320 – 402]	171 [<171 – 196]	140 [123 – 161]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]		
	Formaldehyde	4%	4207 [3270 – 5844]	288 [<i>226 – 383</i>]	111 [<i>93 – 136</i>]	<1 [<i>n/a</i>]	51.6 [<51.6 - 65.9]	1309 [1058 – 1685		
	Formaldehyde + Glutaraldehyde	2% + 1.5%	4227 [<i>3183 – 6027</i>]	39.8 [32.7 – 51.4]	97.9 [<i>82.9 -118</i>]	<1 [<i>n/a</i>]	22.6 [<22.6 – 27.2]	1545 [1164 – 2203		
	Ethanol	100%	63.3 [<i>27.6 – 103</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	8.8 [6.5 – 12.5]		
Other	Methanol	100%	108 [79.5 – 155]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	2.2 [1.9 – 2.5]		
	0.1% PHMB	10:1	30.1 [26.6 - 34.2]	9.5 [8.9 - 10.2]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	<1 [<i>n/a</i>]	9.8 [<9.8 - 11.8]		
	1.0% PHMB	10:1	328 [<i>304 – 356</i>]	132 [111 – 154]	<1 [<i>n/a</i>]	<1 [n/a]	9.3 [<9.3 - 11.1]	203 [<203 – 299]		
	2.0% PHMB	10:1	837 [<837- 1141]	240 [198 – 282]	4.1 [3.7 - 4.5]	<1 [n/a]	25.0 [<20.9 - 29.0]	479 [<479 – 647]		

LB - lysis buffer; TM - transport Medium; nc - not able to be calculated.

Reagent	Virus matrix	Reagent: virus ratio	Contact time (mins)	Titer reduction Log10 (±SE)	Virus detectable in titration [†] (#replicates)	Virus detectable i culture (#replicates)
			10	≥ 4.8 (± 0.1)	Yes (2/3) [¢]	Yes (1/3)
Sigma MM	Tissue culture fluid	1.5:1	30	≥ 4.8 (± 0.1)	Yes (1/3) [¢]	Yes (1/3)
			60	≥ 4.8 (± 0.1)	No (0/3) [¢]	No (0/3)
			10	4.8 (± 0.2)	Yes (3/3)	Yes (3/3)
		1:3	30	5.1 (± 0.2)	Yes (3/3)	Yes (3/3)
- NIAT	T ion of the set () is the set () is the set of th		60	5.2 (± 0.2)	Yes (3/3)	Yes (3/3)
eNAT	Tissue culture fluid		10	≥ 5.1 (± 0.1)	No (0/3)*	Yes (1/3)
		3:1	30	≥ 5.1 (± 0.1)	No (0/3)*	Yes (1/3)
			60	≥ 5.1 (± 0.1)	No (0/3)*	No (0/3)
			10	≥ 5.1 (± 0.2)	No (0/3)*	No (0/3)
Primestore MTM	Tissue culture fluid	1:3	30	≥ 5.1 (± 0.2)	No (0/3)*	No (0/3)
			60	≥ 5.1 (± 0.2)	No (0/3)*	No (0/3)
	Tissue culture fluid	1:1.4	10	4.6 (± 0.1)	Yes (3/3)	Yes (3/3)
Cobas PCR Media			30	4.8 (± 0.1)	Yes (3/3)	Yes (3/3)
			60	4.8 (± 0.1)	Yes (3/3)	Yes (3/3)
			10	≥ 4.4 (± 0.1)	Yes (1/3)	No (0/3)
Aptima Specimen Transport Medium	Tissue culture fluid	5.8:1	30	≥ 4.4 (± 0.1)	No (0/3)	No (0/3)
Transport Mealann			60	≥ 4.4 (± 0.1)	Yes (2/3)	Yes (1/3)
Virus Transport and			10	5.0 (± 0.2)	Yes (3/3)	Yes (3/3)
Preservation Medium	Tissue culture fluid	10:1	30	4.9 (± 0.2)	Yes (3/3)	Yes (3/3)
(Inactivated)			60	4.8 (± 0.2)	Yes (3/3)	Yes (3/3)
			10	≥ 4.8 (± 0.2)	No (0/3)**	tbc
DNA/RNA Shield	Tissue culture fluid	10:1	30	≥ 4.8 (± 0.2)	No (0/3)**	tbc
			60	≥ 4.8 (± 0.2)	No (0/3)**	tbc
2M GITC	Tissue culture fluid	10:1	30	≥ 4.6 (± 0.1)	No (0/3)*	Yes (1/3)
4M GITC	Tissue culture fluid	10:1	30	≥ 5.1 (± 0.2)	No (0/3)*	No (0/3)
40% GHCl	Tissue culture fluid	10:1	30	≥ 4.6 (± 0.1)	Yes (1/3)*	Yes (3/3)

532 Table 2: Virus inactivation by specimen transport tube reagents

 \dagger - samples titrated by TCID50, with a limit of detection of 5 TCID50/mL (0.7 Log10 TCID50/mL) unless stated * - limit of detection was 50 TCID50/mL (1.7 Log10 TCID50/mL) due to cytotoxicity in neat wells of TCID50 assay ** - limit of detection was 504 TCID50/mL (2.7 Log10 TCID50/mL) due to cytotoxicity in neat and -1 wells of TCID50 assay ϕ - titration by plaque assay; limit of detection was 3.3 PFU/mL (0.5 Log10 PFU/mL)

Table 3: Virus inactivation by molecular extraction reagents 537

	•			-		
Reagent	Virus matrix	Reagent: virus ratio	Contact time (mins)	Titer reduction Log10 (±SE)	Virus detectable in titration [†] (#replicates)	Virus detectable in culture (#replicates)
AVL	Tissue culture fluid	4:1	10	5.1 (± 0.1)	Yes (3/3)	Yes (3/3)
AVL + Ethanol	Tissue culture fluid	4:1:4 (AVL:virus: ethanol)	10 ^y	≥ 5.9 (± 0.2)	No (0/3)	No (0/3)
RLT (+BME)	Ferret lung homogenate	9:1	10	≥ 4.9 (± 0.2)	No (0/3)*	No (0/3)
MagNA Pure External LB	Tissue culture fluid	1:1	10	≥ 4.4 (± 0.2)	No (0/3)*	No (0/3)
AL	Tissue culture fluid	1:1	10	≥ 3.5 (± 0.2)	No (0/3)**	No (0/3)
Cobas Omni LYS	Tissue culture fluid	1:1	10	≥ 3.9 (± 0.1)	No (0/3)**	No (0/3)
PHE in-house LB	Tissue culture fluid	4:1	10	≥ 5.6 (± 0.1)	Yes (1/3)*	Yes (2/3)
	Tissue sulture fluid	10:1	30	≥ 5.2 (± 0.2)	No (0/3)*	Yes (2/3)
VPSS (E&O)	Tissue culture fluid	1:1	10	≥ 5.1 (± 0.1)	No (0/3)*	Yes (1/3)
Lysis Buffer (E&O)	Tissue culture fluid	1:1	10	≥ 5.1 (± 0.1)	No (0/3)*	No (0/3)
NeuMoDx Lysis Buffer	Tissue culture fluid	1:1	10	4.3 (± 0.2)	Yes (3/3)*	Yes (3/3)
Samba SCoV LB	Tissue culture fluid	1:1	10	4.8 (± 0.1)	Yes (3/3)	Yes (3/3)
		1:1	10	≥ 5.0 (± 0.1)	Yes (2/3) [¢]	Yes (1/3)
NucliSENS LB	Tissue culture fluid	1:1	30	≥ 5.1 (± 0.0)	No (0/3) [¢]	Yes (1/3)
		2:1	10	≥ 4.9 (± 0.1)	No (0/3)*	No (0/3)
			10	≥ 4.4 (± 0.0)	No (0/3) [¢]	No (0/3)
Panther Fusion	Tissue culture fluid	1.42:1	30	≥ 4.4 (± 0.0)	No (0/3) [¢]	Yes (1/3)
Specimen Lysis Tubes			60	≥ 4.4 (± 0.0)	No (0/3) [¢]	Yes (1/3)
	Pooled swab material	1.42:1	30	≥ 5.1 (± 0.1)	No (0/3)	No (0/3)

 $\overline{LB} - Lysis$ buffer

+ - Syste source
 + - samples titrated by TCID50, with a limit of detection of 5 TCID50/mL (0.7 Log10 TCID50/mL) unless stated
 * - limit of detection was 50 TCID50/mL (1.7 Log10 TCID50/mL) due to cytotoxicity in neat wells of TCID50 assay
 ** - limit of detection was 504 TCID50/mL (2.7 Log10 TCID50/mL) due to cytotoxicity in neat and -1 wells of TCID50 assay

 φ - titration by plaque assay; limit of detection was 3.3 PFU/mL (0.5 Log10 PFU/mL)

Table 4: Virus inactivation by detergents 543

Detergent	Virus matrix	Detergent: virus ratio	Contact time (mins)	Titer reduction Log10 (±SE)	Virus detectable in TCID50 [†] (#replicates)	Virus detectable in culture (#replicates)	RNA integrity‡ (Ct)
Tween 20	Tissue culture fluid	0.1% v/v	30	0.0 (± 0.2)	Yes (3/3)	Yes (3/3)	n.d.
Tween 20	lissue culture fiuld	0.5% v/v	30	0.0 (± 0.2)	Yes (3/3)	Yes (3/3)	+0.2 (±0.0)
		0.1% v/v	30	≥ 4.9 (± 0.1)	Yes (3/3)	Yes (3/3)	n.d.
	The second second second		<2	5.9 (± 0.2)	Yes (3/3)	Yes (3/3)	+0.1 (±0.2)
	Tissue culture fluid	0.5% v/v	10	≥ 6.2 (± 0.2)	No (0/3)	No (0/3)	+1.4 (±0.1)
T.:			30	≥ 6.1 (± 0.2)	No (0/3)	No (0/3)	+3.6 (±0.1)
Triton X-100	Human sera	1.0% v/v	30	1.3 (± 0.2)	Yes (3/3)	Yes (3/3)	n.d.
			60	1.5 (± 0.2)	Yes (3/3)	Yes (3/3)	n.d.
			120	2.0 (± 0.2)	Yes (3/3)	Yes (3/3)	n.d.
	Pooled swab material	0.5% v/v	30	≥ 6.1 (± 0.2)	No (0/3)	tbc	+8.3 (±0.2)
		0.1% v/v	30	5.7 (± 0.1)	Yes (3/3)	Yes (3/3)	+1.3 (±0.2)
SDS	Tissue culture fluid	0.5% v/v	30	≥ 6.5 (± 0.1)	Yes (1/3)	Yes (2/3)	-0.6 (±0.2)
	Pooled swab material	1.0% v/v	30	5.7 (± 0.2)	Yes (3/3)	tbc	+6.1 (±0.0)
	The second second second	0.1% v/v	30	≥ 6.5 (± 0.1)	No (0/3)	No (0/3)	+9.0 (±0.2)
NP40	Tissue culture fluid	0.5% v/v	30	≥ 6.5 (± 0.1)	No (0/3)	No (0/3)	+10.3 (±0.1)
	Pooled swab material	0.5% v/v	30	≥ 6.1 (± 0.2)	No (0/3)	tbc	+8.7 (±0.1)

544 545 546 n.d. - not done

† - limit of detection in TCID50 assay was 5 TCID50/mL (0.7 Log10 TCID50/mL)
 ‡ - difference in Ct in SARS-CoV-specific real-time RT-PCR compared to PBS-treated control, ± standard error

Table 5: Other reagent types 548

Reagent		Virus matrix	Reagent: virus ratio	Contact time (mins)	Titer reduction Log10 (±SE)	Virus detectable in TCID50 ⁺ (#replicates)	Virus detectable in culture (#replicates)
Formaldehyde		Tissue culture fluid	4%	15	≥ 4.8 (± 0.2)	No (0/3)	No (0/3)
				60	≥ 5.0 (± 0.2)	No (0/3)	No (0/3)
			2%	15	≥4.8 (±0.2)	No (0/3)	No (0/3)
				60	≥ 5.0 (± 0.2)	No (0/3)	No (0/3)
		Infected monolayer	4%	15	≥ 6.9 (± 0.2)	Yes (1/3)	Yes (1/3)
				60	≥ 7.5 (± 0.2)	No (0/3)	No (0/3)
			2%	15	≥ 6.8 (± 0.2)	Yes (2/3)	Yes (2/3)
				60	≥ 7.3 (± 0.2)	Yes (2/3)	Yes (3/3)
Formaldehyde + Glutaraldehyde		Tissue culture fluid	2% + 1.5%	60	≥ 5.0 (± 0.2)	No (0/3)	No (0/3)
		Infected monolayer	2% + 1.5%	15	≥ 6.7 (± 0.1)	No (0/3)	No (0/3)
				60	≥ 6.7 (± 0.1)	No (0/3)	No (0/3)
Methanol‡		Infected monolayer	100%	15	≥ 6.7 (± 0.1)	No (0/3)	No (0/3)
РНМВ	0.1%	Tissue culture fluid	10:1	30	1.4 (±0.2)	Yes (3/3)	Yes (3/3)
	1.0%	Tissue culture fluid	10:1	30	1.5 (±0.2)	Yes (3/3)	Yes (3/3)
	2.0%	Tissue culture fluid	10:1	30	1.6 (± 0.2)	Yes (3/3)	Yes (3/3)

549 550

† - limit of detection in TCID50 assay was 5 TCID50/mL (0.7 Log10 TCID50/mL) ‡ - ice cold methanol.

Reagent Type	Reagent	Manufacturer Cat#	Reagent composition	Recommended ratio of sample to reagent
Specimen Transport Tube Reagents	Virus Transport and Preservation Medium (Inactivated)	BioComma Ltd. #YMJ-E	Not known	Swab placed directly into tube containing 3mL reagent
	Sigma MM	Medical Wire Guanidine thiocyanate, Ethanol (concentrations #MWMM unknown)		Up to 1 vol sample to 1.5 vols reagent (up to 0.67:1)
	eNAT	Copan #608CS01R	42.5-45% guanidine thiocyanate, detergent, Tris- EDTA, HEPES.	Swab placed directly into tube containing 1 or 2mL reagent. For urine, 3:1
	Primestore	Longhorn #PS-MTM-3	<50% guanidine thiocyanate, <23% ethanol	1:3
	Cobas PCR	Roche #08042969001	≤40% guanidine hydrochloride, Tris-HCl	Swab placed directly into tube
	Aptima Specimen Transport Medium	Hologic #PRD-03546	Not known	Swab OR 0.5mL VTM sample added to tube containing 2.9mL buffer
	DNA/RNA Shield	Zymo Research #R1100	Not known	1:3
	40% GHCL	Oxoid/Thermo Fisher #EB1351A	28.3% guanidine hydrochloride, 2.1% Triton X-100, Tris-EDTA	Swab placed directly into tube
	2M GITC	Oxoid/Thermo Fisher #EB1349A	18.9% guanidine thiocyanate, 2.4% Triton X-100, Tris-EDTA	Swab placed directly into tube
	4M GITC	Oxoid/Thermo Fisher #EB1350A	31.8% guanidine thiocyanate, 2.0% Triton X-100, Tris-EDTA	Swab placed directly into tube
Molecular Extraction Reagents	NucliSENS Lysis Buffer	Biomerieux #200292	50% guanidine thiocyanate, <2% Triton X-100, <1% EDTA	1:2-1:200
	Panther Fusion	Hologic #PRD-04339	Not known	1:1.42
	Buffer AVL	QIAGEN #19073	50-70% guanidine thiocyanate	1:4
	MagNA Pure 96 External Lysis Buffer	Roche #06374913001	30-50% guanidine thiocyanate, 20-25% Triton X- 100, <100mM Tris-HCl, 0.01% bromophenol blue.	1:1
	Buffer AL	QIAGEN #19075	30-50% guanidine hydrochloride, 0.1-1% maleic acid	1:1
	Cobas Omni LYS	Roche #06997538190	30-50% guanidine thiocyanate, 3-5% dodecyl alcohol, ethoxylated, 1-2.5% dithiothreitol	No instructions for use as off-board lysis buffer
	L6 (Kingfisher formulation)	PHE Media Services	96.6% guanidine thiocyanate, 1.9% Triton X-100, Tris-EDTA	None available
	Buffer RLT	QIAGEN #79216	30-50% guanidine thiocyanate	Tissue to be homogenized directly in undiluted buffer
	NeuMoDx Viral Lysis Buffer	NeuMoDx Molecular,Inc. #401600	<50% guanidine hydrochloride, <5% Tween 20, <1% EDTA, <0.1% sodium azide	1:1
	VPSS	E&O Laboratories #BM1675	Not known	Not known

Not known

E&O Laboratories

#BM1676

551 Supplementary Table 1: Reagent Details

Lysis Buffer

Recommended contact time None given None given None given

None given

None given

None given None given None given

10 mins

10 mins

None given None given None available


None available

None given None given Not known

Not known

Not known

553




554

555 Figure 1: Effectiveness of five filtration matrices at removing cytotoxicity. (A) SARS-CoV-2

virus in clarified cell culture supernatant was treated with indicated reagent for 2mins at room 556 temperature before being purified through one of 5 filtration matrices: Sephadex LH-20 (blue); 557 Sephacryl S400HR (orange); Amicon Ultra 50kDa molecular weight cut off (red); Pierce 558 detergent removal spin columns (DRSC) (purple); or Bio-Bead SM2 (green). Values indicate the 559 percentage toxicity removal after one purification cycle relative to unpurified samples (based on 560 CC20 values – for more details see Table 1). (B) Percentage of input virus remaining in eluate 561 after one purification cycle through each filtration matrix. GHCl - guanidine hydrochloride; 562 GITC - guanidinium isothiocyanate; Tx – Triton X-100; PHMB - polyhexamethylene biguanide; 563 564 SDS - sodium dodecyl sulfate; NP40 - nonyl phenoxypolyethoxylethanol. LB – lysis buffer; TM - transport medium 565

Percentage virus recovery after one filtration step



567

568 Supplementary Figure 1: Cytotoxicity of virus inactivation reagents after passing through

569 **purification matrices.** Concentration-response curves in Vero cells treated with a 2-fold serial

570 dilution of reagent. At 24 h post treatment cell viability was determined, with values normalized

to mock treated cells. Each point represents the mean of triplicate wells, with error bars

indicating standard deviation. Graphs are representative of at least 2 independent experiments.

573 Matrices used: Sephadex LH-20 (blue); Sephacryl S400HR (orange); Amicon Ultra 50kDa

574 molecular weight cut off (red); Pierce detergent removal spin columns (DRSC) (purple); or Bio-

575 Bead SM2 (green). (A) Reagents used in specimen transport tubes: GHCl - guanidine

576 hydrochloride; GITC - guanidinium isothiocyanate; Tx – Triton X-100; TM – Transport Medium

577 (**B**) Reagents used in molecular extraction protocols: PHMB - polyhexamethylene biguanide. (**C**)

578 Detergents commonly used for virus inactivation: SDS - sodium dodecyl sulfate; NP40 - nonyl

579 phenoxypolyethoxylethanol. (D) Other reagents commonly used for virus inactivation.

Dilution Factor (1:10^x)

